Treatment-free follow-up of 24 weeks for all patients
PEGASYSÆ 180 µg sc qw + ribavirin 800 mg qd, 24 weeks
PEGASYSÆ 180 µg sc qw + ribavirin 1000/1200 mg qd, 24 weeks
PEGASYSÆ 180 µg sc qw + ribavirin 1000/1200 mg qd, 48 weeks
PEGASYSÆ 180 µg sc qw + ribavirin 800 mg qd, 48 weeks
A :
B :
D :
C :
Total 1284 patients randomized and treated
| Previous slide | Next slide | Back to first slide | View graphic version |